Table 4 Multivariate (final) Cox proportional hazards model with left truncation assessing the impact of lenalidomide treatment and baseline factors on AML progressiona

From: Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Variable

AML progression

 

HR (95% CI)

P-value

Lenalidomide-treated vs untreated cohort

0.969 (0.483–1.945)

0.930

Cytogenetic complexity (del(5q) plus >1 abnormality vs isolated)

3.555 (1.576–8.022)

0.002

Cytogenetic complexity (del(5q) plus 1 abnormality vs isolated)

1.095 (0.567–2.114)

0.786

Bone marrow blast count (5–10% vs <5%)

2.158 (1.133–4.098)

0.019

RBC transfusion burden, units/8 weeks

1.090 (1.003–1.185)

0.041

Hemoglobin level, g/dl

0.861 (0.736–1.006)

0.059

  1. aLenalidomide treatment, although not significant in the univariate models, was forced to remain in the final models to estimate the magnitude of risk associated with lenalidomide in the presence of other risk factors. Complete covariate data were available for 243 of the lenalidomide-treated patients and 98 of the untreated patients.
Back to article page